{"claim_id": "c0094", "summary": "24–28 weeks screening window; OGTT commonly used", "evidence": [{"pid": "p00103", "doc": "A Comprehensive_Review_of_Gestational_Diabetes_Mellitus.txt", "text": "Although one can develop GDM at any instance during the entire course of pregnancy, it is typically seen between weeks 24 and 28 of pregnancy. Additionally, the prevalence of GDM is growing globally due to an increase in maternal weight gain, maternal age, and inactivity [3]. The etiology of GDM is explained by the maternal pancreas' inability to adjust to the increased insulin demand throughout gestation."}, {"pid": "p00011", "doc": "Management_of_Diabetes_in_Pregnancy_A_Review_of_Clinical_Guidelines_Practices.txt", "text": "Since T2DM often presents without symptoms in its initial stages and women with significant hyperglycemia early in pregnancy face a higher risk of adverse outcomes, early detection and treatment of diabetes are paramount. As a result, most international associations such as the International Association of Diabetes and Pregnancy Study Groups (IADPSG), the American Diabetes Association (ADA), and the World Health Organization (WHO) recommend therefore to screen for overt diabetes at the first antenatal visit using an FPG, HbA1c, or 75 g oral glucose tolerance test (OGTT) with the same cut-offs as for non-pregnant populations. Anyone above the cut-off is considered high risk by interpretation."}]}
{"claim_id": "c0162", "summary": "24–28 weeks", "evidence": [{"pid": "p00015", "doc": "Management_of_Diabetes_in_Pregnancy_A_Review_of_Clinical_Guidelines_Practices.txt", "text": "Both ADA 2023 and NICE 2022 recommend universal screening for GDM between 24-28 weeks of gestation with a 75 g OGTT [10]. However, high-risk populations such as those with a BMI of 30 or more, a family history of diabetes, and a prior history of GDM or macrosomia should undergo screening earlier than 15 weeks of gestation to detect potential glucose intolerance before it worsens [11]. The guidelines of the ADA (2023) recommend the 75 g OGTT with the following cut-off points for diagnosis: fasting glucose ≥92 mg/dL (5.1 mmol/L), a one-hour level of ≥180 mg/dL (10 mmol/L), and a two-hour level of ≥153 mg/dL (8.5 mmol/L)."}, {"pid": "p00094", "doc": "Diabetes_mellitus_and_pregnancy.txt", "text": "[15] Data from the Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) study, correlating blood glucose levels with outcomes will hopefully lead to common agreement on the value for the diagnosis in future.[16] Screening methods for GDM vary from presence of maternal risk factors (table 5) to biochemical screening with 50gm OGTT (1hr blood glucose > 7.8 mmol/l (>140 mg/dl); screening based on maternal risk factors is more cost effective.[15] Table 5. Maternal risk factors for gestational diabetes Obesity Diabetes in first-degree relative Previous infant with macrosomia Previous diagnosis of GDM Age more than 35 years Polycystic ovary syndrome Multiparity Member of high risk population (e.g. Asian or African descent) Open in a new tab Several European centres support a glucose load of 75 gm for diagnosis performed between weeks 24 and 28 of gestation as recommended by the World Health Organization and the Diabetes Pregnancy Study Group of the European Association for the Study of Diabetes.[17] Management of GDM: Treatment of GDM can substantially reduce perinatal morbidity (table 6) from 4% to 1%.[18, 19] Women diagnosed with GDM should receive dietary advice and calorie intake should be reduced if overweight."}]}
{"claim_id": "c0095", "summary": "75g OGTT", "evidence": [{"pid": "p00002", "doc": "Management_of_Diabetes_in_Pregnancy_A_Review_of_Clinical_Guidelines_Practices.txt", "text": "Continuous glucose monitoring (CGM) and insulin pump therapy are valued but burdened by availability and access constraints. A postpartum visit with 75 g oral glucose tolerance test (OGTT) at 4-12 weeks is essential for the detection of persistent diabetes. Variation of diagnostic criteria among guidelines reflects the requirement for standardization."}, {"pid": "p00015", "doc": "Management_of_Diabetes_in_Pregnancy_A_Review_of_Clinical_Guidelines_Practices.txt", "text": "Both ADA 2023 and NICE 2022 recommend universal screening for GDM between 24-28 weeks of gestation with a 75 g OGTT [10]. However, high-risk populations such as those with a BMI of 30 or more, a family history of diabetes, and a prior history of GDM or macrosomia should undergo screening earlier than 15 weeks of gestation to detect potential glucose intolerance before it worsens [11]. The guidelines of the ADA (2023) recommend the 75 g OGTT with the following cut-off points for diagnosis: fasting glucose ≥92 mg/dL (5.1 mmol/L), a one-hour level of ≥180 mg/dL (10 mmol/L), and a two-hour level of ≥153 mg/dL (8.5 mmol/L)."}]}
{"claim_id": "c0171", "summary": "75g 2h OGTT 4-12w postpartum", "evidence": [{"pid": "p00002", "doc": "Management_of_Diabetes_in_Pregnancy_A_Review_of_Clinical_Guidelines_Practices.txt", "text": "Continuous glucose monitoring (CGM) and insulin pump therapy are valued but burdened by availability and access constraints. A postpartum visit with 75 g oral glucose tolerance test (OGTT) at 4-12 weeks is essential for the detection of persistent diabetes. Variation of diagnostic criteria among guidelines reflects the requirement for standardization."}, {"pid": "p00015", "doc": "Management_of_Diabetes_in_Pregnancy_A_Review_of_Clinical_Guidelines_Practices.txt", "text": "Both ADA 2023 and NICE 2022 recommend universal screening for GDM between 24-28 weeks of gestation with a 75 g OGTT [10]. However, high-risk populations such as those with a BMI of 30 or more, a family history of diabetes, and a prior history of GDM or macrosomia should undergo screening earlier than 15 weeks of gestation to detect potential glucose intolerance before it worsens [11]. The guidelines of the ADA (2023) recommend the 75 g OGTT with the following cut-off points for diagnosis: fasting glucose ≥92 mg/dL (5.1 mmol/L), a one-hour level of ≥180 mg/dL (10 mmol/L), and a two-hour level of ≥153 mg/dL (8.5 mmol/L)."}]}
{"claim_id": "c0083", "summary": "postpartum OGTT", "evidence": [{"pid": "p00041", "doc": "Management_of_Diabetes_in_Pregnancy_A_Review_of_Clinical_Guidelines_Practices.txt", "text": "Most guidelines suggest that pregnant women whose GDM is diet-controlled should be delivered at 39-40 weeks of gestation while those with poor control need to be delivered at 37-38 weeks, though the timing may vary based on individual factors, including glycemic control and fetal growth [36]. Postpartum care GDM women should have close follow-up management for the development of chronic diabetes. ADA (2023) recommends a two-hour 75 OGTT at 4-12 weeks after delivery to check whether diabetes has remitted or the mother acquires T2DM, and once-a-year screening for diabetes, as 30-50% develop into T2DM in 10 years [9,37]."}, {"pid": "p00002", "doc": "Management_of_Diabetes_in_Pregnancy_A_Review_of_Clinical_Guidelines_Practices.txt", "text": "Continuous glucose monitoring (CGM) and insulin pump therapy are valued but burdened by availability and access constraints. A postpartum visit with 75 g oral glucose tolerance test (OGTT) at 4-12 weeks is essential for the detection of persistent diabetes. Variation of diagnostic criteria among guidelines reflects the requirement for standardization."}]}
{"claim_id": "c0194", "summary": "screen every 1-3 years", "evidence": [{"pid": "p00018", "doc": "Management_of_Diabetes_in_Pregnancy_A_Review_of_Clinical_Guidelines_Practices.txt", "text": "Further, it is also emphasized in some recommendations that children born to women with GDM have long-term risks of obesity and later development of T2DM, thus requiring follow-up care for many years after delivery [13]. Moreover, children born to women with GDM can inherit type 1 diabetes despite glycemic control [14]. Management of pre-existing diabetes Pre-existing diabetes control consists of optimizing HbA1c before conception, throughout pregnancy, and after delivery in order to prevent congenital malformations and stillbirth as well as for screening complications and education on hypoglycemia."}, {"pid": "p00041", "doc": "Management_of_Diabetes_in_Pregnancy_A_Review_of_Clinical_Guidelines_Practices.txt", "text": "Most guidelines suggest that pregnant women whose GDM is diet-controlled should be delivered at 39-40 weeks of gestation while those with poor control need to be delivered at 37-38 weeks, though the timing may vary based on individual factors, including glycemic control and fetal growth [36]. Postpartum care GDM women should have close follow-up management for the development of chronic diabetes. ADA (2023) recommends a two-hour 75 OGTT at 4-12 weeks after delivery to check whether diabetes has remitted or the mother acquires T2DM, and once-a-year screening for diabetes, as 30-50% develop into T2DM in 10 years [9,37]."}]}
{"claim_id": "c0110", "summary": "OGTT thresholds", "evidence": [{"pid": "p00015", "doc": "Management_of_Diabetes_in_Pregnancy_A_Review_of_Clinical_Guidelines_Practices.txt", "text": "Both ADA 2023 and NICE 2022 recommend universal screening for GDM between 24-28 weeks of gestation with a 75 g OGTT [10]. However, high-risk populations such as those with a BMI of 30 or more, a family history of diabetes, and a prior history of GDM or macrosomia should undergo screening earlier than 15 weeks of gestation to detect potential glucose intolerance before it worsens [11]. The guidelines of the ADA (2023) recommend the 75 g OGTT with the following cut-off points for diagnosis: fasting glucose ≥92 mg/dL (5.1 mmol/L), a one-hour level of ≥180 mg/dL (10 mmol/L), and a two-hour level of ≥153 mg/dL (8.5 mmol/L)."}, {"pid": "p00016", "doc": "Management_of_Diabetes_in_Pregnancy_A_Review_of_Clinical_Guidelines_Practices.txt", "text": "Moreover, WHO’s diagnostic thresholds include fasting glucose ≥92 mg/dL and a two-hour ≥153 mg/dL [11]. Rising GDM incidence correlates with increasing maternal age and obesity. Discrepancies in criteria (e.g., IADPSG vs."}]}
{"claim_id": "c0190", "summary": "OGTT thresholds", "evidence": [{"pid": "p00016", "doc": "Management_of_Diabetes_in_Pregnancy_A_Review_of_Clinical_Guidelines_Practices.txt", "text": "Moreover, WHO’s diagnostic thresholds include fasting glucose ≥92 mg/dL and a two-hour ≥153 mg/dL [11]. Rising GDM incidence correlates with increasing maternal age and obesity. Discrepancies in criteria (e.g., IADPSG vs."}, {"pid": "p00015", "doc": "Management_of_Diabetes_in_Pregnancy_A_Review_of_Clinical_Guidelines_Practices.txt", "text": "Both ADA 2023 and NICE 2022 recommend universal screening for GDM between 24-28 weeks of gestation with a 75 g OGTT [10]. However, high-risk populations such as those with a BMI of 30 or more, a family history of diabetes, and a prior history of GDM or macrosomia should undergo screening earlier than 15 weeks of gestation to detect potential glucose intolerance before it worsens [11]. The guidelines of the ADA (2023) recommend the 75 g OGTT with the following cut-off points for diagnosis: fasting glucose ≥92 mg/dL (5.1 mmol/L), a one-hour level of ≥180 mg/dL (10 mmol/L), and a two-hour level of ≥153 mg/dL (8.5 mmol/L)."}]}
{"claim_id": "c0122", "summary": "OGTT widely used", "evidence": [{"pid": "p00014", "doc": "Management_of_Diabetes_in_Pregnancy_A_Review_of_Clinical_Guidelines_Practices.txt", "text": "Their guidelines also stress the need for a multidisciplinary team to manage diabetes in pregnant women, which may include obstetricians, endocrinologists, dietitians, and diabetes educators [9]. GDM is a common complication of pregnancy, and its usual method of diagnosis is screening for glucose intolerance. The most widely used method is the OGTT."}, {"pid": "p00157", "doc": "A Comprehensive_Review_of_Gestational_Diabetes_Mellitus.txt", "text": "Metzger et al. [14] 2010 This paper can be used as the basis for internationally recognized guidelines for the diagnosis and classification of diabetes during gestation by diabetes, obstetrics, and other organizations. Dabelea et al."}]}
{"claim_id": "c0023", "summary": "maternal risks", "evidence": [{"pid": "p00006", "doc": "Management_of_Diabetes_in_Pregnancy_A_Review_of_Clinical_Guidelines_Practices.txt", "text": "Maternal risks include preeclampsia, cesarean delivery, and worsening of pre-existing diabetes. In contrast, fetal risks include macrosomia, birth defects, preterm birth, neonatal hypoglycemia, and long-term risks such as obesity and type 2 diabetes mellitus (T2DM) later in life [3]. This review compares the guidelines on diabetes management in pregnancy such as preconception care, screening, and therapeutic interventions, emphasizing the need for early intervention and health equity."}, {"pid": "p00017", "doc": "Management_of_Diabetes_in_Pregnancy_A_Review_of_Clinical_Guidelines_Practices.txt", "text": "NICE) contribute to prevalence variability. Despite these minor variations in the diagnostic criteria, early detection and intervention have been agreed upon by both societies as the most crucial factor in the management of GDM [12]. Early detection of the condition allows timely treatment to be instituted that can diminish the risks of maternal complications such as preeclampsia, cesarean delivery, and worsening of pre-existing diabetes, and fetal complications such as macrosomia, birth defects, and neonatal hypoglycemia [10]."}]}
{"claim_id": "c0076", "summary": "neonatal risks", "evidence": [{"pid": "p00095", "doc": "Diabetes_mellitus_and_pregnancy.txt", "text": "Table 6. Perinatal complications of gestational diabetes mellitus Death: still birth and neonatal death Shoulder dystocia Bone fracture Nerve palsy Neonatal hypoglycemia Open in a new tab Such measures will achieve metabolic control in the majority of women. They should monitor their own blood glucose levels and, if the pre-prandial glucose levels are consistently above 5.5mmol/l (95 mg/dl), insulin should be commenced with the aim of keeping pre-prandial blood glucose below 5.5 mmol/l (95 mg/dl), and two hour post-prandial below 7.8 mmol/l (140 mg/dl)."}, {"pid": "p00133", "doc": "A Comprehensive_Review_of_Gestational_Diabetes_Mellitus.txt", "text": "Neonatal complications Neonatal complications can include delivery trauma, such as shoulder dystocia and a brachial plexus wound, as well as potential hypoxia, hypoglycemia, kernicterus, and jaundice. They may also include bacterial infections and newborn respiratory distress syndrome (NRDS) [2]. Neonatal Jaundice Prematurity, inadequate nutrition, and increased enterohepatic circulation of bilirubin due to decreased hepatic conjugation of bilirubin are some factors that may contribute to jaundice."}]}
{"claim_id": "c0114", "summary": "pathway", "evidence": [{"pid": "p00126", "doc": "A Comprehensive_Review_of_Gestational_Diabetes_Mellitus.txt", "text": "Maternal hyperglycemia and hyperinsulinemia can result in alterations in the fetus that are comparable to those found in GDM due to the aforementioned causes, which can result in neonatal obesity [28]. An increase in neonatal size at birth, also known as macrosomia, is the result of excessive nutrition storage. The majority of fat is centered in the fetal abdomen and shoulders."}, {"pid": "p00040", "doc": "Management_of_Diabetes_in_Pregnancy_A_Review_of_Clinical_Guidelines_Practices.txt", "text": "Regular SMBG is recommended to ensure that maternal glucose levels stay within target ranges. Fetal surveillance, including routine ultrasounds every four weeks and a fetal echocardiogram if first-trimester hyperglycemia was present, is particularly important in cases of poor glycemic control or suspected macrosomia, as these conditions increase the risk of complications [35]. Given that macrosomic newborns are more likely to suffer birth complications such as shoulder dystocia, time of delivery is crucial."}]}
